• Objective: We aimed to assess the association between induction chemotherapy (CT) response and survivals and to explore an induction CT response-adapted treatment strategy for localized extranodal NK/T-cell lymphoma (NKTCL) receiving first-line sequential CT and radiation (RT). (aging-us.com)
  • Thus after intensive induction treatment , high- dose chemotherapy in remission may be practicable using stem - cell rescue and may contribute to a further improvement in the outcome in poor- risk as well as average- risk patients with AML. (bvsalud.org)
  • Chemotherapy for AML is broken down into three phases: induction phase, consolidation (or intensification), and maintenance phase. (oncolink.org)
  • Doctors may also recommend this treatment to those with relapsed or resistant AML after they undergo re-induction chemotherapy. (medicalnewstoday.com)
  • For low- and intermediate-risk patients, induction therapy should consist of ATRA and arsenic trioxide (ATO) without chemotherapy. (medscape.com)
  • An important and unanswered question concerns the impact of the number of conventional AML chemotherapy induction cycles to achieve first complete remission on transplant outcomes. (ascopost.com)
  • EA9181, A Phase III Randomized Trial of Steroids+Tyrosine Kinase Inhibitor Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults Rochester, Minn. This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. (mayo.edu)
  • During the course of 3 months after his diagnosis, the patient underwent induction chemotherapy with remission and prolonged periods of count recovery. (cdc.gov)
  • Drug treatment designed to further diminish the disease toward complete remission following INDUCTION CHEMOTHERAPY. (bvsalud.org)
  • It helps to consolidate the gains during induction chemotherapy and may be followed by MAINTENANCE CHEMOTHERAPY. (bvsalud.org)
  • Lower maternal educational level was associated with increased frequency of mucositis, as were induction chemotherapy and maintenance chemotherapy after relapse. (bvsalud.org)
  • Oral lesions were associated with the induction phase of chemotherapy. (bvsalud.org)
  • the median time from remission to relapse was 13 months and 15 months, respectively (P = 0.023, log rank test). (nih.gov)
  • The 6-month remission rate (RR 1.09, 95% CI 0.86 to 1.38, p=0.48), the 6-month ANCA negativity (RR 1.31, 95% CI 0.91 to 1.90, p=0.15) and the long-term relapse rate (RR 1.36, 95% CI 0.80 to 2.31, p=0.26) were all similar between the two treatments. (bmj.com)
  • Treatment options are intended to help with symptoms, maintain remission, and prevent relapse. (wikipedia.org)
  • The goal of maintenance is to prevent relapse and keep you in remission. (oncolink.org)
  • Consolidation therapy is based on the potential risk of relapse in patients who undergo induction therapy. (medscape.com)
  • The children with INS were divided into 3 groups of 20: first presentation, remission and relapse. (who.int)
  • The purpose of this study is to compare relapse-free survival between participants with FLT3/ITD AML in first morphologic complete remission (CR1) who undergo hematopoietic stem cell transplant (HCT) and are randomized to receive gilteritinib or placebo beginning after the time of engraftment for a two year period. (mayo.edu)
  • 0.001), as compared to initial partial remission or non-response. (aging-us.com)
  • 6 Patients achieved complete remission and 2 partial remission. (karger.com)
  • Conclusion: Deep remission from induction CT was associated with favorable survivals in localized NKTCL receiving CT+RT, and an induction CT response-adapted individualized treatment strategy might be recommended in clinical practice. (aging-us.com)
  • Budesonide 9mg gastro-resistant granules are in clinical development for the induction of remission in patients with lymphocytic colitis. (nihr.ac.uk)
  • In one phase III clinical trial, budesonide was shown to be significantly effective in inducing clinical remission in lymphocytic colitis patients in comparison to a placebo. (nihr.ac.uk)
  • The effect of high fiber, low refined carbohydrates, lowmicroparticle diet, low calcium diet, symptoms-guided diet and highly restricted organic diet on clinical remission in active CD is uncertain. (johnshopkins.edu)
  • To use data from clinical genomic sequencing of diagnosis, germline/remission and MRD samples to guide therapy, including incorporation of targeted agents and institution of genetic counseling and cancer surveillance. (centerwatch.com)
  • Szpirt WM, Heaf JG, Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis - a clinical randomized controlled trial. (smw.ch)
  • After 6 weeks, 76.7% of participants achieved clinical remission, which means that their symptoms significantly reduced. (healthline.com)
  • Rather, it is a clinical state that TNF- plays a pathogenic role in the characterized by heavy proteinuria and induction and/or maintenance of glomeru- hypoalbuminaemia, often associated with lar barrier dysfunction [ 8 ]. (who.int)
  • Week 14 clinical remission was attained in 10/25 (40%) of VDZ-aTNF patients versus 23/50 (46%) of VDZ patients (OR = 0.8, 95% CI 0.3-2.1, P = 0.6) and clinical response in 19/25 (76%) versus 39/50 (78%) respectively (OR = 0.9, 95% CI 0.3-2.7, P = 0.8). (medscape.com)
  • This initial treatment aims to clear as many leukemia cells as possible in the blood and bone marrow and to induce remission. (medicalnewstoday.com)
  • Budesonide rectal foam is used to help get mild to moderate active ulcerative colitis that extends from the rectum to the sigmoid colon under control (induce remission). (mayoclinic.org)
  • 53% women) received at least 2 courses of RTX to treat GPA relapses or to maintain remission. (elsevierpure.com)
  • [ 3 ] Approximately 90% of patients with GPA respond to cyclophosphamide, with approximately 75% experiencing complete remission. (medscape.com)
  • Since introduced by Fauci et al in the 1970s, oral cyclophosphamide in combination with high-dose glucocorticoids (ie, prednisone 1mg/kg/day) has been the criterion standard for induction of remission in AAV. (medscape.com)
  • Eventually, intravenous cyclophosphamide was investigated as an alternative to oral cyclophosphamide in an effort to decrease treatment-associated toxicities, and, while the emphasis has been placed on optimizing treatment by minimizing exposure to cyclophosphamide and seeking alternative comparable therapies, the combination of cyclophosphamide (intravenous or oral) and glucocorticoids remained the recommended therapy for induction of remission in generalized/severe GPA for years. (medscape.com)
  • In 2011, however, the US Food and Drug Administration (FDA) approved the use of rituximab (a monoclonal antibody that targets B cells), in combination with glucocorticoids, as an alternative to cyclophosphamide for induction of remission in AAV (GPA and microscopic polyangiitis). (medscape.com)
  • Cytoxan ( cyclophosphamide ) and corticosteroids are frequently used as part of induction therapy nowadays. (medicinenet.com)
  • The efficacy of intensive immunosuppressive therapy with agents such as cyclophosphamide (CYC) or rituximab (RTX) has been established as a remission-inducing therapy in patients with organ/life-threatening AAV 1-5 and is recommended as a conventional therapy. (bmj.com)
  • More than 90 percent of individuals with this once-devastating disease experience remission after they receive cyclophosphamide-based therapy," says Dr. Fauci. (nih.gov)
  • Recently, the monoclonal antibody rituximab was approved for the treatment of GPA and MPA, providing the first major alternative to cyclophosphamide for induction therapy of AAV. (smw.ch)
  • With considerable advances in therapy, including the introduction of ATRA initially as a single agent and then in combination with anthracyclines, and more recently by development of arsenic trioxide (ATO)-containing regimens, APL is now characterized by complete remission rates of 90% and cure rates of ∼ 80%, even higher among low-risk patients. (nature.com)
  • The drug was shown to be effective with 70% of the patients achieving complete remission. (centerwatch.com)
  • At a median follow-up time of 16 months, 68% of patients who had achieved complete remission were still alive and 58% were disease free. (centerwatch.com)
  • Treatment with ATRA should be continued until terminal differentiation of blasts and achievement of complete remission. (medscape.com)
  • To determine the tolerability of combination therapy with ruxolitinib and Early Intensification therapy in patients with activation of JAK-STAT signaling that can be inhibited by ruxolitinib and Day 15 or Day 22 MRD ≥5%, Day 42 MRD ≥1%, or LLy patients without complete response at the End of Induction and all patients with early T cell precursor leukemia. (centerwatch.com)
  • Retrospective analysis by the Center for International Blood and Marrow Transplant Research (CIBMTR): Prompt complete remission plus consolidation therapy yields improved survival after allogeneic hematopoietic cell transplantation (allo-HCT) for patients with acute myeloid leukemia (AML) receiving a myeloablative conditioning regimen and not a reduced-intensity conditioning regimen. (ascopost.com)
  • Similarly, the outcomes of myeloablative conditioning and reduced-intensity conditioning regimens for allo-HCT and their relationship with pretransplant consolidation cycles for patients in first complete remission are also unknown. (ascopost.com)
  • 01). Treatment-related mortality was similar for patients with primary induction failure vs those in first complete remission after myeloablative or reduced-intensity conditioning allo-HCT (Table 1). (ascopost.com)
  • This large retrospective analysis on behalf of the CIBMTR shows again that among patients eligible for allo-HCT, only one induction cycle to achieve first complete remis sion, particularly when combined with one consolidation therapy, is associated with better outcomes after myeloablative conditioning and not reduced-intensity conditioning. (ascopost.com)
  • Compared with the poor outcomes of patients who received allo-HCT during refractory (active) disease, the outcomes of patients who received more than one induction cycle to achieve complete remission is somewhat better but remains unsatisfactory. (ascopost.com)
  • The purpose of this study is to evaluate the rate of complete MRD response by flow cytometry after 4 weekly doses of daratumumab-hyaluronidase (Day 29) among patients with MRD positive T-ALL in hematologic morphologic complete remission or complete remission with incomplete hematologic recovery. (mayo.edu)
  • 22 of these (91%) entered a complete remission (CR). (lu.se)
  • Its main goal is to convert morphologic and cytogenetic remission into durable molecular remission. (medscape.com)
  • Objective This study was conducted to evaluate the efficacy and safety of repeated and prolonged B cell depletion with rituximab (RTX) for the maintenance of long-term remission in patients with chronic relapsing granulomatosis with polyangiitis (Wegener's) (GPA). (elsevierpure.com)
  • Cochrane Abstracts , Evidence Central , evidence.unboundmedicine.com/evidence/view/Cochrane/439007/all/Traditional_corticosteroids_for_induction_of_remission_in_Crohn's_disease. (unboundmedicine.com)
  • Intensive induction therapy in acute myeloid leukemia (AML) as in some other systemic malignancies is a strategy fundamentally different from post-remission strategies . (bvsalud.org)
  • The MTX regimen used in the present study was less effective for induction of remission in patients with extensive disease and pulmonary involvement and was associated with more relapses than the CYC regimen after termination of treatment. (nih.gov)
  • Additionally, treatment recommendations are different for induction of remission and maintenance of remission. (medscape.com)
  • Approaches such as consolidation treatment , prolonged maintenance , and autologous or allogeneic transplantation in first remission are directed against the minimal residual disease in which a malignant cell population has survived induction treatment and shows resistance due to special genetic or kinetic features. (bvsalud.org)
  • Therefore, in AML the introduction of intensification strategies into the induction phase of treatment has been suggested as a new step in addition to intensification in the postremission phase. (bvsalud.org)
  • As expected from the dose effects observed in post-remission treatment with high- dose cytarabine (AraC) or longer treatment , similar dose effects have been found in induction treatment both from the incorporation of high- dose AraC and from the double-induction strategy used in patients up to 60 years of age. (bvsalud.org)
  • A corresponding dose effect in the induction treatment of patients aged 60 years and older has been found with daunorubicin 60 vs 30 mg/m2 as part of the thioguanine / AraC/ daunorubicin (TAD) regimen with the higher dosage significantly increasing the response rate and survival in these older patients who represent a poor- risk group as a whole. (bvsalud.org)
  • after a remission, you will enter this second phase of treatment. (oncolink.org)
  • Total remission was reached, on average, within two months after treatment with Trisenox began. (centerwatch.com)
  • Treatment of APL includes induction therapy, consolidation therapy, and maintenance therapy. (medscape.com)
  • The first phase of treatment is induction of remission and the second phase of treatment is maintenance. (openpr.com)
  • This guideline provides recommendations for remission induction and maintenance therapy as well as adjunctive treatment strategies in GPA, MPA, and EGPA. (bvsalud.org)
  • Conclusion RTX appeared to be effective and safe for the induction and maintenance of remission in patients with chronic relapsing GPA. (elsevierpure.com)
  • People with Crohn's disease experience chronic recurring periods of flare-ups and remission. (wikipedia.org)
  • Remission induction therapy: the more intensive the better? (bvsalud.org)
  • In contrast, induction therapy deals with naive tumor cells possibly different from their counterparts in remission in terms of their kinetic status and sensitivity . (bvsalud.org)
  • Thus we have been able to demonstrate both in younger and older patients that a poor prognosis can be improved by a more intensive induction therapy . (bvsalud.org)
  • We conducted a systematic review and meta-analysis to assess the efficacy of MMF as a remission induction therapy in patients with AAV comparing it with the efficacy of CYC. (bmj.com)
  • MMF may be an alternative remission induction therapy in patients with non-life-threatening AAV. (bmj.com)
  • In 1973, daunorubicin (DNR) was shown to increase remission rates from 13 to 58% and to reduce hemorrhage-related mortality after 5 days of therapy relative to 6-MP-based regimens. (nature.com)
  • Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. (springer.com)
  • Second, we wanted to find a less toxic therapy that also will prolong remission. (nih.gov)
  • The goal of this therapy is to put you in remission. (oncolink.org)
  • Induction therapy should not be modified based on the presence of leukemia cell characteristics that have variably been considered to predict a poorer prognosis (eg, secondary chromosomal abnormalities, FLT3 mutations, CD56 expression, BCR3 PML-RARA isoform). (medscape.com)
  • Conclusions Vedolizumab/anti-TNF co-exposure did not generate new safety signals during 14-weeks induction, nor did it reduce efficacy or alter vedolizumab pharmacokinetics. (medscape.com)
  • Early studies with induction including 6-mercatopurine (6-MP) alone or in combination with steroids, methyl-glyoxal guanyl hydrazine and/or methotrexate led to poor results. (nature.com)
  • As a particular effect, patients with poor- risk AML according to an unfavorable karyotype , high LDH in serum , or a delayed response show longer survival following double induction containing high- dose AraC as compared to standard- dose AraC. (bvsalud.org)
  • Pulse versus daily oral CyP for induction of remission in ANCA-associated vasculitis. (ox.ac.uk)
  • At 6 months, the remission rate in patients treated with MTX (89.8%) was not inferior to that in patients treated with CYC (93.5%) (P = 0.041). (nih.gov)
  • These recommendations include the use of rituximab for remission induction and maintenance in severe GPA and MPA and the use of mepolizumab in nonsevere EGPA. (bvsalud.org)
  • The primary end point was the remission rate at 6 months (noninferiority testing). (nih.gov)
  • All medication dosages may be gradually decreased in individuals who have experienced continuous remission for 12 months. (medicinenet.com)
  • Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. (cochrane.org)
  • High- dose AraC in induction, however, exhibits cumulative toxicity in that repeated courses containing high- dose AraC in the post-remission period lead to long-lasting aplasias of about 6 weeks. (bvsalud.org)
  • Future prospective studies are required to test different strategies that can improve the rates and quality (based on measurable residual disease [MRD] assessment) of remissions prior to and after allo-HCT using less toxic and more effective induction, conditioning, and maintenance therapies. (ascopost.com)
  • The use of RTX for the maintenance of long-term remission merits further formal investigation. (elsevierpure.com)
  • American College of Rheumatology [ACR] responder status) with the value of evaluating absolute disease activity states (e.g., remission). (nih.gov)
  • Within the ACR50 and ACR70 responder groups, functional disability and radiographic progression were lowest in patients who had attained disease remission at 1 year, compared with those who had attained low or moderate disease activity. (nih.gov)
  • In the MTX group, remission was delayed among patients with more extensive disease (P = 0.04) or pulmonary involvement (P = 0.03). (nih.gov)
  • First, we wanted to induce disease remission and reduce or eliminate maintenance steroid use. (nih.gov)
  • In this retrospective analysis, the investigators assessed the impact of the number of induction and consolidation cycles and disease status on the success of allo-HCT in 3,113 patients with AML from 2008 to 2019. (ascopost.com)